reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
=== Food === Before being introduced into the aquarium trade, the dwarf, along with the snakeskin gourami was and still is a popular food fish in its native range. In Bangladesh it is known as "Kholisha" and "Khosti" in India and "Kungee" in Punjab as well as different linguistic variants within its range.
== Manufacturing == Paper-based microfluidic devices can be manufactured based on the dimensions, i.e. 2D and 3D. To fabricate 2D paper-based microfluidics, variations of methods, such as wax printing, inkjet printing, photolithography, flexographic printing, plasma treatment, laser treatment, etching (microfabrication), screen printing, digital light processing (DLP) 3-D printer, and wax screening, have been employed. Further lamination of multiple paper microfluidics creates pseudo-3D microfluidics that could provide an additional dimension of the fluidic network and increase the complexity. Each technique aims to create hydrophobic physical barriers on hydrophilic paper that passively transport aqueous solutions. Biological and chemical reagents must then be deposited selectively along the device by either dipping the substrate into a reagent solution or locally spotting a reagent onto the substrate.
=== Tom Wolsey === Tom Wolsey (Harry Hadden-Paton) is the newly-appointed CEO of Pierpoint, brought on to help steer the firm through its debt crisis. Tom assembles an emergency committee of senior executives to help salvage Pierpoint when its stock plummets the day of its 150th anniversary. After several failed attempts to find a buyer for the firm, Eric finally brokers a sale with Al-Mi'raj, a firm representing the Egyptian sovereign wealth fund. Tom is fired as CEO because the Egyptian government would not approve of his homosexuality.
An L-ribonucleic acid aptamer (L-RNA aptamer, trade name Spiegelmer) is an RNA-like molecule built from L-ribose units. It is an artificial oligonucleotide named for being a mirror image of natural oligonucleotides. L-RNA aptamers are a form of aptamers. Due to their L-nucleotides, they are highly resistant to degradation by nucleases. L-RNA aptamers are considered potential drugs and are currently being tested in clinical trials.
Half-Life was Valve's debut title and the first to use GoldSrc. It received critical acclaim, winning over fifty PC Game of the Year awards. The game was followed up with two expansions, Half-Life: Opposing Force and Half-Life: Blue Shift, both of which ran GoldSrc and were developed by Gearbox Software. Half-Life: Decay, an expansion pack for Half-Life only released on PlayStation 2, was released in 2001 alongside Half-Life's debut on the platform. Unlike other games in the series, it never received an official version for Windows, however an unofficial version of the game was released by independent developers in 2008. Half-Life: Decay was the final iteration in the Half-Life series to run on GoldSrc, with all future entries in the series using the Source and Source 2 engines.
Sources: en.wikipedia.org
via glucuronidation (30–50%): valproic acid β-O-glucuronide via beta oxidation (>40%): 2E-ene-valproic acid, 2Z-ene-valproic acid, 3-hydroxyvalproic acid, 3-oxovalproic acid via omega oxidation: 5-hydroxyvalproic acid, 2-propyl-glutaric acid some others: 3E-ene-valproic acid, 3Z-ene-valproic acid, 4-ene-valproic acid, 4-hydroxyvalproic acid All in all, over 20 metabolites are known. In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate. The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose. Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine. Only a small amount is excreted via the faeces. Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers.
In December 2024, the Auditor General of Ontario questioned the financial prudence of the relocation. Contrary to the Ford government's business plan analysis, which projected $257 million in savings over 50 years, the AG found that relocation costs have already exceeded the anticipated savings, reaching approximately $400 million.In May 2025, the Canadian Architect magazine reported that draft versions of the structural engineering report by Rimkus Consulting that the Ontario government had relied on in deciding to close the centre, had originally recommended routine repairs and not closure, up until May 2024. This revelation was added to earlier reporting from Global News that Infrastructure Ontario had been in frequent communication with Rimkus in the leadup to the public release of the report in June 2024, and led the magazine to conclude that the language describing the consequences of not doing the routine repair that was later used to justify the closure had been inserted after political pressure. In February 2026, Ford unveiled the designs of the new building and announced that a contract had been awarded for its construction. It will cost an estimated $1 billion and will be smaller than the original facility, with a footprint of about 400,000 square feet. The Centre would also incorporate the Ontario Place pods as exhibit space and the Cinesphere. The proposed move has been controversial.
== Non-cytokine examples of macrophage-activating factors == Pathogenic antigens can bind to toll-like receptors that stimulate macrophage activation and response. Examples include heat shock proteins released during apoptosis, and bacterial lipopolysaccharide.
== External links == Media related to Artocarpus lacucha at Wikimedia Commons Data related to Artocarpus lacucha at Wikispecies Antioxidant and toxicity activities of Artocarpus lakoocha Roxb. heartwood extract Fruit with foliage Crops for the Future: Barhal (Artocarpus lakoocha)[link removed]
Junior doctors in England vote to strike in their ongoing dispute for a 26% pay rise, and will stage a 72-hour walkout. The BMA maintains junior doctors' pay has been cut by 26% since 2008 after inflation is considered. 21 February The UK Government announces that it had a budget surplus in January, with £5bn more in revenue than predicted. A planned 48-hour strike by nurses in England is called off to allow the Royal College of Nursing and Department of Health and Social Care to enter into renewed negotiations. The broadcasting regulator Ofcom writes to both ITV News and Sky News to ask them for an explanation of their actions following complaints made by the family of Nicola Bulley. Her family had been contacted by both outlets despite asking for privacy. Asda and Morrisons announce they are limiting the sale of some fruit and vegetable products, such as tomatoes, peppers and cucumbers, because of a shortage caused by severe weather in Spain and North Africa which has affected harvests. The UK Government recommends a 3.5% pay rise for public sector workers in England, below the rate of inflation. 22 February Shamima Begum loses her legal challenge to overturn the decision to remove her UK citizenship. Tesco and Aldi Süd follow Asda and Morrisons by introducing limits on the purchase of some fruit and vegetables. Lancashire Police and Crime Commissioner Andrew Snowden commissions the College of Policing to review the force's investigation into the disappearance of Nicola Bulley, including the release of information about her private life.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.